(300 WORDS MAX.) Yuma Therapeutics is a privately held biotechnology company focused on developing drugs to treat Alzheimer's disease (AD) and other neurodegenerative diseases. The Company's approach is to reduce the production of phosphorylated tau (p-tau) protein which is observed in many AD patients and believed to be involved in the memory loss and learning. By reducing p-tau production, we believe we could improve the daily lives of AD patients. We are ready to test our novel small molecule compound in animal model of AD.